newsfilter
← Latest News
Business Wire·

AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease

ILAP intended to accelerate regulatory review process and facilitate patient access in U.K. for seriously debilitating and life-threatening diseases AVR-RD-02 has previously received Fast Track status from U.S. FDA and